While many of the parents chose to speak anonymously to protect their children’s privacy, they were eager to share their ...

The DHSC has a published list of currently available and unavailable ADHD products in England that it regularly updates. It says: "We have provided comprehensive guidance to healthcare ...

"We are anticipating that there will be intermittent disruption across our ADHD products into April 2024. "For full clarity, this does not mean that no stock is available until April 2024 ...

No Serious Adverse Events ReportedSubmission of New Drug Application Targeted for Mid 2025 KANSAS CITY, Kan., Jan. 07, 2025 ...

Other ADHD products in its portfolio include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Adzenys-ER (amphetamine) extended-release oral suspension. The company ...

With the submission of Qelbree ®, we continue to further strengthen our ADHD portfolio, offering a range of products designed to meet the diverse needs of patients.” According to IQVIA Canada ...

According to IQVIA Canada, the total Canadian market of non-stimulant ADHD products was $83.5M in 2023. Prescriptions in the Canadian non-stimulant ADHD market grew 10% in 2023 versus 2022 and grew at ...

With the submission of Qelbree ®, we continue to further strengthen our ADHD portfolio, offering a range of products designed to meet the diverse needs of patients.” According to IQVIA Canada, the ...

With the submission of Qelbree ®, we continue to further strengthen our ADHD portfolio, offering a range of products designed to meet the diverse needs of patients." According to IQVIA Canada ...